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Antibiotic prophylaxis for endocarditis: time to reconsider
J Singh,* I Straznicky,† M Avent,‡ AN Goss§
Abstract
Some cardiac conditions require antibiotic
prophylaxis for some types of dental treatment to
reduce the risk of infective endocarditis (IE). All
medical and dental practitioners are familiar with
this practice but tend to use different regimens in
apparently similar circumstances. Generally, the
trend has been to prescribe antibiotics if in doubt.
This review explores the evidence for antibiotic
prophylaxis to prevent IE: does it work and is it
safe? The changing nature of IE, the role of
bacteraemia of oral origin and the safety of
antibiotics are also reviewed. Most developed
countries have national guidelines and their points
of similarity and difference are discussed. One can
only agree with the authority who describes
antibiotic guidelines for endocarditis as being ‘like
the Dead Sea Scrolls, they are fragmentary,
imperfect, capable of various interpretations and
(mainly) missing!’ Clinical case-controlled studies
show that the more widely antibiotics are used, the
greater the risk of adverse reactions exceeding the
risk of IE. However, the consensus is that antibiotic
prophylaxis is mandatory for a small number of
high-risk cardiac and high-risk dental procedures.
There are a large number of low-risk cardiac and
dental procedures in which the risk of adverse
reactions to the antibiotics exceeds the risk of IE,
where prophylaxis should not be provided. There is
an intermediate group of cardiac and dental
procedures for which careful individual evaluation
should be made to determine whether IE or
antibiotics pose the greater risk. These categories are
presented. All medical and dental practitioners need
to reconsider their approach in light of these current
findings.
Key words: Antibiotic prophylaxis, endocarditis, dental
treatment.
Abbreviations and acronyms: IE = infective endocarditis.
Aust Dent J 2005;50 Suppl 2:S60-S68
clinical experience that various authorities, medical and
dental practitioners will end up with different
treatment proposals for apparently similar patients.
This was evidenced by a recent survey of Australian
dental practitioners who had little consensus on which
were the risk procedures, which were the risk cardiac
conditions and which was the appropriate antibiotic
regimen.1 National guidelines exist in most major
Western countries including the United States of
America,2,3 the United Kingdom,4 and the Netherlands.5
Australia does not appear to have a current set of
guidelines which are universally acceptable.6-9 This has
led to individual institutions developing their own
guidelines.10 As a consequence, one authority has
described antibiotic guidelines for endocarditis
prophylaxis as being ‘. . . like the Dead Sea Scrolls, they
are fragmentary, imperfect, capable of various
interpretations and (mainly) missing!’11
A scientific review was recently conducted by the
Cochrane Group.12 When they examined a large
number of papers against the strict evidence-based
criteria used by the Cochrane Group, they concluded
that ‘there is no evidence about whether penicillin
prophylaxis is effective or ineffective against bacterial
endocarditis in people who are at risk, and who are
about to undergo invasive dental procedures’. If,
however, one follows the Cochrane conclusions then a
few susceptible patients would develop IE with a
consequent high risk of death or significant morbidity.13
The medical or dental practitioner who did not provide
antibiotic cover may then find themselves at medico-
legal risk for negligent practice.14 Alternatively, if one
takes the commonly held view that it is safer to provide
antibiotic cover for just about all types of dental
treatment for all types of cardiac conditions, then one
places a different group of patients at risk of death from
anaphylaxis. In a recent quantitative analysis it was
found that three times as many would die from
anaphylaxis if all were given antibiotics as would
develop IE if they were not given antibiotic
prophylaxis.15
Consequently, there is a need to carefully re-examine
the evidence for under which circumstances one can
best protect patients from either serious harm from IE
or from antibiotics. Does prophylaxis work and is it
safe? In the attempt to answer these questions it is first
necessary to understand all aspects of the process.
Hence, in this paper we will review the pathogenesis of
IE, the clinical condition of IE, the causes and types of
bacteraemia (particularly those of oral origin), the
issues relating to antibiotics, current risk benefit studies
of IE antibiotic prophylaxis, current international and
INTRODUCTION
Traditionally, it has been recommended that
antibiotic prophylaxis should be given for some types
of invasive dental treatment in patients with some types
of cardiac conditions which may be susceptible to the
development of infective endocarditis (IE). However,
this is easier to say than it is to apply. It is a common
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national guidelines and, finally, make some current
recommendations based as much as possible on the
evidence.
The pathogenesis of infectious endocarditis
In a comprehensive review of the pathogenesis of
IE,16 the usual process was divided into the following
steps: endocardial damage; establishment and
persistence of bacteria within the endocardium;
bacterial growth with local tissue damage; and the
establishment of clinical IE with both cardiac and
peripheral non-cardiac manifestations.
Endocardial damage
The normal endothelium is a single layer of cells
derived from mesoderm which lines the cavity of the
heart and lumen of all blood vessels. Its integrity is
fundamental to maintaining homeostasis and normal
circulatory function. The metabolic and synthetic
properties of endothelial cells help to regulate
inflammation, remodelling, vascular tone and
coagulation. The normal endothelium is a non-
thrombogenic surface and is resistant to colonization
by circulating bacteria.17,18 Endothelial cell injury or
dysfunction activates metabolic and synthetic events
associated with many vascular disorders.19 The most
common causes of endothelial cell damage are
haemodynamic and occur in regions of extreme
mechanical or shear stress.20 These are the flow surfaces
of valves along the lines of closure on the systemic side
of the circulation. Thus the most common sites are the
mitral and aortic valves, ventricular septal defects and
complex congenital abnormalities. The assessment of
haemodynamic flow disorders by echocardiography
has recently been reviewed in an Australian series of
dental patients who had been previously told they
needed antibiotic prophylaxis for IE. It was found that
70 per cent had normal hearts and only 15 per cent
required antibiotic prophylaxis.21
Changes in the endothelial cells are greater if there is
an underlying change in the connective tissues of the
valves. Scanning electron microscopy of diseased valve
leaflets show abnormal morphology including
alterations in shape, microvilli, discontinuity of cell
borders and desquamation.22,23 These morphological
changes increase the thrombogenicity of the valve, as
well as the intracellular permeability, and possibly
change the cellular synthetic functions. The
inflammatory activation of these endothelial cells
further disrupts the endothelial cell barrier and causes
thrombotic vegetations to develop on the surfaces of
the valves. These vegetations further alter the
haemodynamic properties of the valves, and are an
ideal nidus for bacterial adherence and colonization
and the source of emboli.16
These changes are maximal in previously damaged
valves such as in patients who have had valve scarring
from rheumatic fever or who have had previous
bacterial endocarditis. Artificial materials as used in
prosthetic heart valves and other intra-cardiac devices
are particularly thrombogenic.24
Establishment and persistence of bacteria within the
endocardium
Transient bacteraemia originating from the various
bacterially-infested sites in the body (i.e., the mouth,
respiratory system, gut, skin and genito-urinary system)
are ubiquitous. The bacteria are usually rapidly
destroyed in the blood and if they reach the heart they
pass through without settling. Sometimes, however,
when there is a combination of a high load of bacteria
within the blood, more virulent bacteria with a greater
capacity to adhere to damaged valves, or altered
haemodynamics and thrombus formation on damaged
valves or foreign bodies, then bacteria may settle and
commence colonization. Bacteria with the greatest
ability to adhere to damaged valves are Staphylococcus
aureus, streptococcus species and enterococci. Together
they are responsible for 80 per cent of IE cases.25
Bacterial growth
Once the valve is colonized the bacteria must survive
and avoid the host defences.  Maturation of the
vegetation is a key event in the process, where the
micro-organisms become fully enveloped and thus
protected from cellular and soluble host defence
systems.26 Both staphylococci and streptococci can
trigger tissue factor production from local monocytes
and induce platelet aggregation. Bacterially-induced
platelet activation both helps to envelop the bacteria
and to release proteins which are bactericidal. Thus
bacteria associated with IE need to be resistant to
platelet-induced factors.
In some cases IE may occur in the presence of an
intact, normal endothelium. This is seen with virulent
invasive pathogens such as Staphylococcus aureus or
micro-organisms capable of parasitising endothelium,
such as Coxiella burneti, the agent of Q fever. This is,
however, not an issue in IE of dental origin.
Clinically, IE occurs in 50 per cent of cases with no
clinically identifiable history of underlying valvular
damage.27 Only 4-19 per cent of patients with IE have
had a surgical procedure (including dental procedures)
in the related time period.28 Thus, the ‘usual’
pathogenesis of IE has been described, but it is by no
means certain and is arguably an ‘unusual’ pathway.
Clinical infectious endocarditis
A number of clinical descriptive names have been
used for IE, namely, bacterial endocarditis, acute
bacterial endocarditis, subacute endocarditis and
chronic endocarditis. Practically, these are evidence of
the variable presentation of the clinical disease, but
essentially they are the same process. The essential issue
of endocarditis is that there is a microbiological
infection of the endothelium of the heart.13,16 If IE is
untreated then it is invariably fatal. With intensive
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modern management IE still has a significant mortality
rate of the order of 25-50 per cent. Survivors
commonly need surgical replacement of their damaged
heart valves.
The incidence of IE in Western countries is estimated
to be 1.7 to 6.2 cases per 100 000 person years.13,29 The
higher incidence is mainly associated with intravenous
drug use. The incidence in this group is estimated to be
150 to 2000 per 100 000 person years, and can be
higher among persons with known valvular disease.
This group is also known to have a high incidence of
blood-borne viral diseases which further increases their
risk. There is also a higher risk associated with
increasing age and greater use of prosthetic heart
valves.30 There has been a marked decrease however in
rheumatic fever in Western countries. Indeed, with the
ability to prevent further episodes of rheumatic fever
with antibiotics, and the general reduction in rheumatic
fever incidence in Western countries, the prevalence of
rheumatic valvular disease is declining and is now
confined to an ageing cohort of patients affected in
their youth, and to specific groups such as Australian
Aborigines, Pacific Islanders and certain migrant
groups. Thus, the emphasis placed by most dentists on
asking patients whether they have rheumatic fever is
now unwarranted.31
The characteristic lesions of IE are valvular
vegetations which are composed of collections of
platelets, fibrin, micro-organisms and inflammatory
cells. It most commonly occurs on damaged or
prosthetic heart valves, but may also occur on normal
valves, on septal defects, on chordae, tendinae or on
mural endocardium.13,16
The clinical presentation of IE is highly variable and
spans a continuum from subacute to acute and
fulminating. Fever is the most common symptom.
Other less common symptoms include anorexia, weight
loss, malaise and night sweats. Most sufferers have a
heart murmur (which may have been pre-existing),
splenomegaly or petechiae of the skin, conjunctiva or
oral mucosa.
The specific cardiac manifestations are heart
murmurs which may be pre-existing or new regurgitant
murmurs from further valvular damage or ruptured
chordae. Congestive heart failure develops in 30-40 per
cent of patients, usually as a consequence of valvular
dysfunction, but occasionally due to endocarditis-
associated myocarditis, or an intra-cardiac fistula.
Progression of heart failure is variable dependent on the
severity of the valvular dysfunction. Aortic valve
dysfunction progresses more rapidly than mitral valve
dysfunction. Pericarditis may occur from abscesses
burrowing through the epicardium. Heart block may
occur from interruption of the conduction system.
Myocardial infarction may uncommonly occur from
embolisation of a coronary artery.
The non-cardiac manifestations, particularly the
non-suppurative peripheral manifestations, are less
commonly seen these days due to earlier diagnosis and
aggressive treatment. Arterial emboli are clinically
apparent in approximately 50 per cent of patients.
These are more likely in mitral valve vegetations,
particularly if the vegetation is larger than 10mm.
Neurologic symptoms are most often secondary to
embolic strokes and occur in 40 per cent of patients.
Immune complex deposition on the glomerula
basement membrane causes hypocomplementemic
glomerulo-nephritis and renal dysfunction.
The diagnosis of IE requires integration of clinical,
laboratory and echocardiographic data. A specific and
highly sensitive diagnostic schema known as the Duke
criteria has been developed to assist diagnosis.32
Treatment involves prolonged parental administration
of antimicrobial agents, either singly or in combination.
Antibiotic treatment either as an in-patient or, when
fever and the major cardiovascular problems have
resolved, as an outpatient, should continue for at least
two months. Cardiac surgery is commonly required.13
The mortality rate varies according to the virulence of
the organisms involved, the presence of complications
or co-existing conditions, the extent of the cardiac
infection and the appropriateness of combined medical
and surgical treatment. Generally, with aggressive
modern treatment in a centre of cardiac excellence, the
mortality rate is 20-25 per cent. Recurrence of IE may
occur with a low rate (2 per cent) for penicillin
susceptible streptococci viridans, but there is a higher
relapse rate (10-15 per cent) for prosthetic valve
endocarditis.
Causes of bacteraemia
All surface coverings of the body are colonized by a
unique microflora. Thus, any bacteraemia may be of
skin, gut, airway, genito-urinary or oral origin. Bacteria
from these sources frequently enter the blood on a
physiologic basis as a transient bacteraemia, and are
dealt with by the host defences. 
This review will only consider the bacteraemia of
oral origin, although, as noted, the relative frequency of
oral causes has decreased. Transient bacteraemias that
follow normal physiological activities such as chewing
are usually cleared by the host defences within 10
minutes.33 With normal physiologic function of the
mouth there are about 5000+ minutes of transient
bacteraemia in a month (or 8 per cent of the time).
Generally, the probability of this causing IE is
exceedingly low, but it is greater in a patient with pre-
existing valve damage, in particular a prosthetic valve.
Oral manipulations including dental treatment will
produce a greater bacteraemia than physiologic
function. Usually they are still relatively low grade and
of short duration. A simple dental extraction with
healthy gingivae produces 1 to 100 colony producing
units per millilitre of blood, for less than 10 minutes.34
Tooth extraction for patients with chronic periodontal
disease results in a greater bacterial load. This
association has been demonstrated in rats with induced
aortic valve vegetations. Animals with experimental
gingivitis were at a greater risk of post-extraction
endocarditis than those with healthy gingivae.35
The frequency of bacteraemia associated with
various dental procedures and oral manipulations is
presented in Table 1.36,37 It should be noted that there is
a wide range of values between different studies. This
makes a difference as to how sophisticated the
bacteriological techniques are. If anaerobic techniques
are added then a wider range and greater extent of
bacteraemia is demonstrated. The time at which blood
is taken for analysis and the frequency in a single
patient are also key values to examine when reviewing
bacteraemia studies.
Traditionally, the criteria that ‘significant bleeding’
associates with a dental procedure has been equated
with a significant bacteraemia. A recent study which
involved both pre- and post-procedure bacteraemia
estimations showed that bleeding is a poor predictor of
odontogenic bacteraemia above usual physiologic
levels.38
Issues in antibiotic prophylaxis
The rationale for the use of antibiotic prophylaxis for
surgical, including dental, manipulations is that the
procedures cause bacteraemia and the bacteraemia may
cause endocarditis. As a result, the antibiotics should be
given to susceptible patients before the bacteraemia is
generated. These steps have been demonstrated in
animal studies but it remains an unanswered question
as to whether or not this reflects what occurs in
humans.
Mechanism of prevention
Antibiotics may prevent endocarditis either by killing
bacteria or by damaging them to an extent that the host
defences can then destroy them. Therefore, the
antibiotic may work before the bacteria enter the
bloodstream, after they enter the bloodstream or on
colonies of bacteria. The primary mechanism by which
antibiotic prophylaxis could occur has not been
established but a number of studies show that
bacteraemia is reduced both in quantity and time in the
presence of antibiotics. However it is most likely that,
as they may prevent bacterial adherence, antibiotics
primarily work on bacterial colonies within the
endocardium.
Adverse reactions to antibiotics
All drugs carry risks, although in the past this has
usually not been considered highly by medical and
dental practitioners. The risks associated with
antibiotics are side effects such as gastro-intestinal tract
upset, colonization of resistant or fungal strains, drug
interactions, allergic reactions (including anaphylaxis)
and death. Mild reactions, including urticaria, occur in
0.7-10 per cent of penicillin courses, with a usual range
of 1-3 per cent.39 This rate has increased over time.
Anaphylactic reactions occur in 0.011-0.04 per cent of
patients receiving penicillin for prophylaxis. Ten per
cent of cases of anaphylaxis result in death.40 Thus, the
most common antibiotic recommended for prophylaxis
will cause harm for some patients.
Allergic reactions are rare with vancomycin41 and
gentamicin42 but both are associated with side effects
such as nephro- and oto-toxicity.
Resistant organisms
The development of resistant organisms is also a real
problem. Recent indiscriminant use of antibiotics has
resulted in an increase in the prevalence of penicillin-
resistant streptococcus viridans in blood cultures. In a
study of 31 Japanese children who had cardiac disease
and who were at risk from IE, and thus had received a
number of episodes of antibiotic prophylaxis, it was
found that 61 per cent of them had resistant
streptococcus viridans in their oral flora.43 Overall,
however, the contribution of inappropriate dental
prescription is significantly less than the medical
contribution, and, in turn, this is vastly less than issues
relating to the use of antibiotics in agricultural
animals.44
Clinical trials on effectiveness and safety
Randomized placebo-controlled studies have not
been undertaken since the number of patients required
would be large (not less than 6000 patients) and there
are ethical issues related to the lethality of the disease.45
Case-controlled studies, when matched to patients in
the community who are not at risk, are a more practical
way of evaluating risk. In a large study in the USA it
was found that dental treatment did not appear to be a
risk factor for IE, even in patients with valvular
abnormalities. There did seem to be a risk associated
with dental extractions although the numbers were
small. It was confirmed that cardiac valvular
abnormalities were a strong risk factor for IE.46 An
extensive case-control study in The Netherlands,47,48
which was the only study to meet the Cochrane
Criteria,12 concluded that there is no evidence to
support whether penicillin prophylaxis is effective or
ineffective against bacterial endocarditis in people at
risk who are about to undergo an invasive dental
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Table 1. Incidence of bacteraemia following oral














Periodontal disease (patient resting) 11%
Periodontal disease (resting but anaerobic technique) 60-80%
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procedure. Similar equivocal results, although the
Cochrane group excluded this study on methodological
grounds, were reported by another European group.49
There are no comparable Australian case-control
studies.
In a risk benefit analysis it was indicated that if
penicillin prophylaxis was given to all patients with
mitral valve prolapse, irrespective of whether they had
significant regurgitation or not, then three times as
many deaths would occur from anaphylaxis than if no
prophylaxis had been given.15 Some patients who were
given prophylaxis still developed endocarditis.15 In a
further study the annual mortality rate of IE of dental
origin in the general community was compared with
the incidence attributable to antibiotic prophylaxis in
patients with rheumatic cardiopathy undergoing dental
treatment.50 They found that in a population of 100
million people there would be approximately 26 deaths
attributed to IE associated with dental treatment.
However, if 100 million people with rheumatic
cardiopathy went to their dentist once per year, and
were administered penicillin prophylactic cover, then
there would be approximately 4000 deaths. Thus,
based on these calculations (which include a number of
hypothetical assumptions), the risk of prophylaxis
would greatly exceed the risk of death from
endocarditis. These assumptions are that all of the
population would go to the dentist on an annual basis,
all would receive intravenous penicillin and that
resuscitation would be unsuccessful. In practical terms
the risks would be much lower than that. It has also
been found that if patients are assessed to determine
whether they have a history of penicillin allergy there
would have been no reported cases of anaphylactic
allergy provoked by the administration of a single dose
of 2g amoxycillin.51 However, this is not a matter which
one would routinely report. In the authors’ institution,
which provides dental treatment for a large number of
high-risk cardiac patients, there have been a number of
unreported adverse reactions.
Cost-benefit analysis
A number of studies have been conducted to look at
the cost-benefit analysis of antibiotic prophylaxis. One
involved a comparison of parenteral penicillin to
erythromycin for patients with mitral valve prolapse.15
This found that parenteral penicillin would cause more
deaths from anaphylactic reactions than would result
from endocarditis if no prophylaxis was given or if oral
erythromycin was given. This study did not take into
account the bacteriostatic nature of erythromycin. It is
for this reason that erythromycin is no longer
recommended. It also did not take into account the
gastro-intestinal side effects associated with
erythromycin. A further study52 comparing penicillin
prophylaxis for mitral valve prolapse patients resulted
in a greater net loss of life due to death from
anaphylaxis, particularly in younger patients. In older
patients prophylaxis with oral penicillin may save some
years of life but at a higher cost.52 There have been no
studies of a risk-benefit analysis for high-risk cardiac
lesions, but the conclusions of studies to date confirm
that unless the cost per intervention is very low then the
cost per case prevented is extremely high.
It is on this basis that Durack, who has extensive
clinical and research experience in IE, has suggested
that antibiotic prophylaxis should only be given for
high-risk dental procedures in high-risk cases.53
Although this policy would result in a small but
probably unmeasurable increase in the incidence of IE,
it would reduce the risk of death from anaphylaxis and
the cost of antibiotic treatment.
Review of current guidelines
The major international2-5 and Australian6-10
guidelines have been reviewed and are summarized into
Tables 2, 3, 4 and 5.
The USA,2,3 British4 and Netherlands5 guidelines were
all formulated by high level multidisciplinary groups of
experts. The principal scientific studies have been
performed particularly in the Netherlands but also in
the United States. The several Australian guidelines6-10
are of variable quality. The Australian Prescriber wall
chart, being old, primarily focused on antibiotic
regimens, and although they are aimed to be read at a
glance, they are not easy to follow.6 Similarly, the
Australian Dental Association (ADA) guidelines are not
easy to follow without study and assumed knowledge.7
Table 2. Guideline recommendations – Cardiac conditions
High Risk Moderate Risk Low or No Risk










Systemic – pulmonary shunts 
• Mitral valve prolapse with
clinically significant mitral
regurgitation4,5,9
• Congenital cardiac malformations2-4,7,10
other than those defined as high or low risk
• Acquired valvular dysfunction2-4,7
(i.e., rheumatic heart disease)
• Hypertrophic cardiomyopathy2-5,7,10
• Mitral valve prolapse2,3,7,10 with valvular
regurgitation or thickness leaflets
• Aortic stenosis4
• Mitral regurgitation4
• Septal defects and patent ductus arteriosus
• Isolated secondary atrial septal defects2-4,7,9,10
• Surgical repair of septal defects2-4,7,9,10
(arterial/ventricular and patient ductus
arteriosus)
• Previous coronary artery bypass graft2-4,7,9,10
• Mitral valve prolapse2-4,7,9,10
• Physiologic, functional or innocent2-4,7,9 murmur
• Previous Kawasaki disease2,3,7,9,10 without
valvular dysfunction




The ADA pamphlet does not make recommendations
but generally tends to favour the provision of
antibiotics, particularly if there is uncertainty.8 The
most recent therapeutic group is appropriately
multidisciplinary and simple,9 but has been challenged
as it may be too simple and possibly provides
inadequate cover for high risk cases.54 The author’s
institution, which is the specialist tertiary referral
centre for both cardiac and oral problems in South
Australia, has developed its own institutional
guidelines.10 These were produced to combat a previous
circumstance of individual opinion resulting in widely
variable prescribing routines for apparently identical
cases. It has been only partially successful and
individual variations continue to exist at all levels of
experience, both medically and dentally. Sadly, this
probably reflects the fate of most guidelines. They are
issued, sometimes read, but variably applied.
On review of the international and national
guidelines it is clear that there are many points of
agreement. All agree that there is a high-risk cardiac
group where the risk of endocarditis exceeds the risk of
antibiotic prophylaxis from dental at-risk procedures,
thus warranting antibiotic prophylaxis. There are,
however, some variations as to which conditions
constitute high-risk cardiac states.
All agree that there is a large group of patients with
a cardiac history who are at no greater risk of
endocarditis than the general population. In these
patients the risk of anaphylaxis and similar adverse
events from the antibiotic prophylaxis is demonstrably
greater than the risk of endocarditis. Thus, in these
circumstances, antibiotic prophylaxis is not warranted
for any type of dental treatment.
There is then, however, an intermediate zone of
moderate-risk cardiac problems which have a risk of
endocarditis greater than the general population. If
given antibiotic prophylaxis they also have a risk of
adverse reaction to the antibiotic. The balance of risk
for these patients is difficult, if not impossible, to assess
as their risk to benefit is about equal.
In regard to dental interventions there is consensus
that dental manipulations of either the hard or soft
tissues will result in a bacteraemia. All agree that
extractions and periodontal treatment do result in a
significant bacteraemia and thus will present a risk of
endocarditis to susceptible cases. However, there are
variations as to where exactly to draw the line. The
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Table 3. Guideline recommendations – dental procedures
Dental procedures requiring prophylaxis Dental procedures not requiring prophylaxis
• Dental extraction2-5,7,9,10 • Restorative dentistry2,3,5,7,9,10 (with or without retraction cord)
• Periodontal procedure2-5,7,9,10 (including probing and recall)2-4,9 • Local anaesthetic injections2-4,7,9,10
• Dental implants2-5,7,10 • Intracanal endodontics2-4,9
• Replantation of avulsed teeth2-5,7,9,10 • Placement of rubber dam2,3,9
• Endodontic treatment beyond the apex2-5,7,9,10 • Post-operative suture removal2-4,10
• Apicectomy2,3,5,7,9 • Placement of prosthesis2-5,7,9,10
• Subgingival placement of a/b fibres and strips2-4 • Placement of orthodontic devices and brackets2,3,5,7,9,10
• Initial placement of orthodontic bands2-4,9 • Orthodontic adjustments7,9,10
• Intraligamentary LA injections2-4,7,9,10 • Impressions2-4,9,10
• Prophylactic cleaning of teeth2-4 and implants where bleeding anticipated • Fluoride treatment2-4,7,9,10
• Rubber dam placement4,10 • Oral radiographs2-4,7,9,10
• Matrix bands and wedging • Shedding primary teeth2-5,7,9
• Gingival retraction cord4 • Dental examination4,9
• Surgical drainage abscess9,10 • Biopsy4
• Drainage of an abscess4
• Brushing and flossing2,3,9
Table 4. Guideline recommendations – antibiotic regimens
High-Risk Cardiac Medium-Risk Cardiac
• Amoxycillin oral 2g3,4 1 hour prior to procedure Amoxycillin oral 2g3-5,10 1 hour prior to procedure
• For highest risk i.e., prosthetic valve or previous endocarditis Amoxycillin oral 3g5-8 1 hour prior to procedure
Amoxycillin 2g IV4 and Gentamicin 1.5mg/kg IV before procedure Amoxycillin oral 2g10 followed by 1g 6 hours later
• Amoxycillin 1g IV8
Gentamicin 2mg/kg IV 30 minutes before procedure followed
by 500mg oral
• Amoxycillin 2g11 oral
Gentamicin 2mg/kg IV
For patients with penicillin hypersensitivity
Clindamycin oral 600mg3-6 1 hour before procedure Clindamycin oral 600mg3-6,10,11 1 hour before procedure
Cephalexin oral 2g3,4 1 hour before procedure (not if have immediate Cephalexin oral 2g3-4 1 hour before procedure (not if have 
type hypersensitivity) immediate type hypersensitivity)
Vancomycin 1g slow infusion IV7 Clindamycin oral 600mg7,8 1 hour before procedure
Gentamicin 1.5mg/kg IV and 300mg 6 hours later
Clindamycin 600mg IV11 Erythromycin 800mg8 1 hour before procedure
Gentamicin 2mg/kg IV
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primary examples are gingival manipulations, involving
restorative dentistry such as matrix bands, placement
of rubber dam and clamps or ligatures. These vary
between the different guidelines.
There is also general consensus as to those
procedures which have only a physiologic level of
bacteraemia and thus do not require prophylaxis.
Again there are some differences. One, which is
difficult to understand or to accept, is that a dental
abscess is not recommended for prophylaxis under the
British guidelines.4 In a patient with an abscess beyond
the confines of the tooth, who also has a cardiac
indication for prophylaxis, there would appear to be a
clear indication for appropriate dental treatment to
eliminate the cause of the abscess but also adjunctive
antibiotics for both therapeutic and prophylaxis
reasons.
There are some points of consensus on the choice of
antibiotic dose and route for prophylaxis. If it is
indicated then an appropriate antibiotic should be
chosen to cover the most likely causative organisms,
i.e., the oral flora. It should be administered in a
sufficiently high dose prior to the commencement of the
procedure in order to achieve adequate serum
concentrations in the bloodstream when bacterial
contamination is at its highest. There is little value from
a follow-up dose on the same day. Antibiotics in the
preceding days and days after the procedure are not
clinically indicated as they offer no additional
advantage.
There is some disagreement as to whether antibiotic
prophylaxis should be different for high or medium-
risk cardiac indications. The current trend is toward
treating these two groups similarly with a pre-
procedure dose of amoxycillin and a follow-up dose for
high-risk cases. There is evidence that 2g is equivalent
to 3g oral amoxicillin with less risk of nausea.55
Practically, if one is using the single 3g oral liquid
preparation, and the patient is not nauseated, then the
full dose is administered. Currently, some very high-risk
cardiac patients undergoing high-risk dental procedures
in the Oral and Maxillofacial Surgery Unit in South
Australia have intravenous antibiotic prophylaxis,
usually with gentamicin and amoxycillin. These
patients are usually having multiple extractions for
gross oral sepsis immediately prior to valve surgery. It
is accepted that the provision of intravenous antibiotics
is difficult in general dental and medical practice and
that gentamicin is primarily used for synergy for
enterococcal infections. General practitioners treating
patients in high-risk cardiac and dental categories
should carefully consider whether specialist referral is
in the patient’s best interest. Antibiotic regimens are
presented in Table 6.
CONCLUSIONS
Essentially, the decision to administer antibiotic
prophylaxis is an individual matter and a careful
assessment needs to be made on an evidence-based risk
assessment, not on anecdote, traditional belief, or what
medical and dental practitioners were taught as
undergraduates. The cardiac risk should be assessed
medically, preferably by a cardiologist, using current
investigative technology, for example echocardio-
graphy.21 The oral risk should be assessed dentally, both
clinically and radiographically. Patients who are at
Table 5. Guideline recommendations – antibiotic recommendations – paediatric. Note – Dosage is dependent on
patient size
High Medium
• Amoxycillin 50mg/kg2,3,5,7 • Amoxycillin 50mg/kg2,3,5,9
Oral up to 2g 1 hour before procedure Oral up to 2g 1 hour before procedure
• Amoxycillin 1.5g4 • Amoxycillin 1.5g4
Highest risk give 1g Amoxycillin IV /+ Gentamicin 1.5mg/kg followed by IV • Amoxycillin maximum 2g9
Amoxycillin 1g or Oral 1g
Allergic to penicillin:
Clindamycin 20mg/kg2-3 Clindamycin 20mg/kg2,3
Cephalosporin 50mg/kg Cephalosporin 50mg/kg2,3
Clindamycin 300mg4,5 Clindamycin 300mg4,5
Vancomycin 20mg/kg IV6 Clindamycin 10mg/kg to 2g9
Gentamicin 2.5mg/kg IV per day (up to 80mg per dose maximum)
Table 6. Antibiotic regimens
Antibiotic regimen selected after careful evaluation of both the
cardiac condition and the dental procedure
Standard prophylaxis
Amoxycillin 2g orally as a single dose 1 hour before procedure.
For paediatric patients Amoxycillin 50mg/kg up to 2g orally as a
single dose 1 hour before the procedure.
Or
If hypersensitive to penicillin or on long-term penicillin therapy or
had a related beta-lactan antibiotic more than once in the previous
month:
Clindamycin 600mg orally as a single dose 1 hour before
procedure.
For paediatric patients clindamycin 15mg/kg up to 600mg orally as
a single dose 1 hour before procedure
For high-risk cardiac having a high-risk dental procedure
Consider the addition of:
Gentamicin 2mg/kg IV before procedure to either
Amoxycillin 1g IV or
Clindamycin 600 mg IV
For patients under general anaesthesia
Amoxycillin 1gm I/V
Or
Clindamycin 600mg I/V or
Lincomycin 600mg IV
All just before procedure
cardiac risk should be made dentally fit. The at-risk
dental procedures should be performed, in one, or at
most two, sessions, with modification of the dental
treatment plan, as necessary, to accomplish this. The
patient needs to be kept dentally fit by the instruction of
good oral hygiene practices and perhaps the use of
antiseptic mouth rinses prior to procedures.56 The patient
who is at a cardiac risk needs to be informed of the risk
both from the cardiac condition and the adverse reaction
to antibiotics point of view. The patient needs to
understand that they have a responsibility for their
ongoing oral health maintenance. In the absence of a
patient accepting responsibility, the dental treatment
plan should be modified toward extractions.
On this basis all patients can be divided into one of
three groups: high-risk cardiac patients having high-risk
dental procedures for which antibiotic prophylaxis is
mandatory (Table 7); low-risk cardiac condition having
any type of dental treatment for which antibiotic
prophylaxis is not indicated as the risk is no greater than
for the general population (Table 8); and intermediate
risk from both cardiac and the dental point of view for
which individual decisions need to be made about the
risk benefit of antibiotic prophylaxis (Table 9).
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